|
|
|
|
|
30.06.26 - 18:18
|
Intel, AMD Jump 7% as Chip Stocks Catch a Risk-On Bid (24/7 Wall St.)
|
|
|
Chip stocks are catching a strong risk-on bid at midday Tuesday, with mega-cap semiconductors leading the broader tape higher. Intel (NASDAQ:INTC) stock is up 7% to $140.56, while Advanced Micro Devices (NASDAQ:AMD) stock is up 7% to $577.13. The leveraged sector proxy is moving even harder. Direxion Daily Semiconductor Bull 3X Shares (NYSEARCA:SOXL) shares are ... Intel, AMD Jump 7% as Chip Stocks Catch a Risk-On Bid...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.06.26 - 01:36
|
Arm says it tops 50% share in hyperscale cloud as x86 grip slips (Digitimes)
|
|
|
Arm Holdings says its chip architecture has crossed the 50% threshold in the hyperscale cloud market, a milestone in a segment long dominated by Intel and AMD. The SoftBank-backed chip designer is now pushing further into the hardware business itself, even as supply chains strain under the weight of the AI infrastructure buildout....
|
|
|
29.06.26 - 21:00
|
Tesla’s 10% Weight in ARKK Sets Up a Make-or-Break Year for the Innovation ETF (24/7 Wall St.)
|
|
|
The ARK Innovation ETF (NYSEARCA:ARKK) has barely moved this year, gaining about 2% year to date through late June and sitting at roughly $78 per share. That stasis hides a violent tug of war inside the portfolio: AMD has more than doubled, up 144% YTD, while Coinbase has shed 34% and Tesla (NASDAQ:TSLA), ARKK's largest ... Tesla's 10% Weight in ARKK Sets Up a Make-or-Break Year for the Innovation ETF...
|
|
|
|
|
|
|
|
|
29.06.26 - 17:18
|
AMD Aktie: KI-Boom entfacht neue Kursfantasie! (Aktiencheck)
|
|
|
New York (www.aktiencheck.de) - AMD-Aktienanalyse von Cantor Fitzgerald:
Der Analyst C.J. Muse von Cantor Fitzgerald habe das Kursziel für die Aktie von Advanced Micro Devices Inc. (AMD) (ISIN: US0079031078, WKN: 863186, Ticker-Symbol: AMD, NASDAQ-Symbol: AMD) von 500 auf 700 USD erhlht und und das Rating "overweight" beibehalten. [mehr]...
|
|
|
29.06.26 - 14:03
|
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD (GlobeNewswire EN)
|
|
|
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced enrollment completion for 4FRONT-2, the second Phase 3 clinical trial in our global program, evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD)....
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
